ClinicaliQ Trial Snapshot
- Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL) — Active Not Recruiting • Phase III • NCT06073821.
- New drug combination (sonrotoclax plus zanubrutinib) tested against standard treatment (venetoclax plus obinutuzumab) for chronic lymphocytic leukaemia.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The main objective of this study is to compare the efficacy of sonrotoclax plus zanubrutinib versus venetoclax plus obinutuzumab in participants with chronic lymphocytic leukemia (CLL) Conditions: CLL Interventions: Sonrotoclax, Zanubrutinib, Venetoclax, Obinutuzumab Lead Sponsor: BeOne Medicines Planned Enrollment: 652 participants